Stockscreener 앱 받기
5.29
10.94%
-0.65
시간 외 거래:
5.24
-0.05
-0.95%
Curis Inc 주식(CRIS)의 최신 뉴스
Curis stock edges into a thin-day update. - AD HOC NEWS
CRIS Q1 2026 Earnings: Wider Than Expected Loss Sends Shares LowerEarnings Yield Analysis - dars.gov.et
Curis Consents 6 Patients in Phase 2 Trial of Emavusertib in Chronic Lymphocytic Leukemia - Moomoo
Curis (CRIS) Advances TakeAim CLL Study with Patient Enrollment Progress - GuruFocus
Curis Achieves Key Milestone in TakeAim CLL Study - Intellectia AI
Curis Consents First Six Patients in TakeAim CLL Study - PR Newswire
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split - AOL.com
Curis Inc outlines oncology pipeline as investors watch funding and trial progress - AD HOC NEWS
Curis Implements 1-for-20 Reverse Stock Split - TipRanks
Curis (NASDAQ: CRIS) sets 1-for-20 reverse split and adjusts equity awards - Stock Titan
Why did Curis (CRIS) stock soar after hours? - MSN
Why Did Curis (CRIS) Stock Soar After Hours? - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Curis (CRIS) schedules reverse stock split and split-adjusted trading - Stock Titan
Curis Stockholders Approve 1-for-20 Reverse Split - TipRanks
Curis (NASDAQ: CRIS) sets 1-for-20 reverse stock split after holder vote - Stock Titan
CRIS Q1 2026 Earnings: Significant Earnings Miss Amid No Reported RevenueEarnings Call Q&A - dars.gov.et
Curis opens 11 sites for emavusertib combo in TakeAim CLL trial - Yahoo Finance
$Curis (CRIS.US)$ cold blooded 🤣 - Moomoo
Curis opens 11 sites for CLL study, shareholders approve stock split - Investing.com South Africa
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
$Curis (CRIS.US)$ 💎 in the rough - Moomoo
Curis (CRIS) Launches Phase 2 CLL Study and Plans Reverse Stock Split - GuruFocus
Curis announces eleven active clinical sites in TakeAim CLL study - TipRanks
Price to sales forward of Curis, Inc. – NASDAQ:CRIS - TradingView
Curis, Inc. Actuals & Estimates (MUN:CUS0) - TradingView
Enterprise value to EBIT forward of Curis, Inc. – NASDAQ:CRIS - TradingView
CUS0 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Curis, Inc. – LS:A3ETJD - TradingView
Curis Shareholders Approve Flexible Reverse Stock Split Authorization - TipRanks
[8-K] CURIS INC Reports Material Event - Stock Titan
Curis (CRIS) EGM 2026 Summary - Quartr
CRIS: Reverse stock split and adjournment proposals were both approved by majority vote - TradingView
Curis Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
Price to earnings forward of Curis, Inc. – NASDAQ:CRIS - TradingView
CRIS Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Curis, Inc. – LS:A3ETJD - TradingView
Enterprise value to revenue forward of Curis, Inc. – NASDAQ:CRIS - TradingView
Curis (CRIS) Stock Faces Mixed Analyst Target Changes Over Execution And Pipeline Risk - Yahoo Finance
Curis Inc. (CRIS) Edges Higher: Testing Key Resistance Amid Speculative TradingBreakout Stock Alerts - dars.gov.et
Curis StockAnalyst focus and biotech sector review - AD HOC NEWS
Curis Inc (CRIS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Curis Inc (CRIS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Curis Inc (CRIS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Curis Inc (CRIS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Curis Inc (CRIS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Curis Inc (CRIS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Curis Inc (CRIS) Institutional Confidence - TradingKey
Curis Inc (CRIS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Curis Inc (CRIS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Curis Inc Stock (US2312691006): Quarterly earnings keep biotech micro-cap in focus - AD HOC NEWS
CRIS Q1 2026 Earnings: Deep EPS Miss Highlights Pre-Revenue Challenges Amid Strategic PivotQuarterly Earnings - newsline.com
Curis stock (US2312691006): Cancer biotech faces Nasdaq compliance deadline after reverse stock spli - AD HOC NEWS
Q1 2026 Curis Inc Earnings Call Transcript - GuruFocus
Curis (NASDAQ: CRIS) plans reverse stock split to address Nasdaq bid price - Stock Titan
Curis (CRIS) Q1 2026 Earnings Call Transcript - The Globe and Mail
CRIS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Curis Inc. (CRIS) Surges 8.33%: Momentum Builds Above Key SupportVolatility Stop - newsline.com
CRIS News | CURIS INC (NASDAQ:CRIS) - ChartMill
CRIS Q1 2026 Earnings: Significant EPS Miss Highlights Ongoing Pre-Revenue ChallengesEarnings Deceleration Risk - The Legal Advocate
CRIS Q1 2026 Earnings: Development-Stage Biotech Posts Wider-than-Expected Loss with No RevenueEPS Surprise History - newsline.com
CRIS Q1 2026 Earnings: Significant EPS Miss as Biotech Advances Pipeline Without RevenueRevenue Per Share - The Legal Advocate
CRISCuris Inc Stock Price and Quote - Finviz
Curis Inc. Q1 2026 Earnings: Deep EPS Miss as Pre-Revenue Biotech Continues DevelopmentShare Dilution Risk - Newser
1.17%
2.48%
자본화:
|
볼륨(24시간):